Ratio Therapeutics
Developing best-in-class radiopharmaceuticals for cancer treatment
$70MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Developing best-in-class radiopharmaceuticals for cancer treatment
Develops lead-212 targeted alpha therapies to treat cancer
Develops medicines targeting historically undruggable protein targets in cancer
Pitching Catalio Capital Management? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room